JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

BSX

100.99

-1.37%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

BSX

100.99

-1.37%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

BSX

100.99

-1.37%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

BSX

100.99

-1.37%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

BSX

100.99

-1.37%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

Search

Kala Pharmaceuticals Inc

Închisă

0.81 3.85

Rezumat

Modificarea prețului

24h

Curent

Minim

0.77

Maxim

0.82

Indicatori cheie

By Trading Economics

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+931.25% upside

Dividende

By Dow Jones

Următoarele câștiguri

10 nov. 2025

Kala Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

28 oct. 2025, 23:50 UTC

Acțiuni populare

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 oct. 2025, 23:25 UTC

Câștiguri

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 oct. 2025, 23:18 UTC

Câștiguri

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 oct. 2025, 22:20 UTC

Câștiguri

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 oct. 2025, 22:13 UTC

Câștiguri

Wal-Mart de Mexico Net Profit Falls in 3Q

28 oct. 2025, 21:38 UTC

Câștiguri

Correction to Visa Sales Jump Article

28 oct. 2025, 21:17 UTC

Câștiguri

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 oct. 2025, 21:07 UTC

Câștiguri

Visa Sales Jump as Consumers Keep Spending -- Update

28 oct. 2025, 21:02 UTC

Câștiguri

Mondelez Tempers Outlook as Costs Rise

28 oct. 2025, 23:51 UTC

Market Talk

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 oct. 2025, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 oct. 2025, 23:02 UTC

Câștiguri

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 oct. 2025, 23:01 UTC

Câștiguri

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 oct. 2025, 22:46 UTC

Câștiguri

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 oct. 2025, 22:45 UTC

Câștiguri

SK Hynix 3Q Net KRW12.6T >000660.SE

28 oct. 2025, 22:44 UTC

Câștiguri

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 oct. 2025, 22:43 UTC

Câștiguri

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 oct. 2025, 22:42 UTC

Câștiguri

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 oct. 2025, 22:40 UTC

Câștiguri

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 oct. 2025, 22:40 UTC

Câștiguri

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 oct. 2025, 22:22 UTC

Câștiguri

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 oct. 2025, 22:22 UTC

Câștiguri

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 oct. 2025, 22:22 UTC

Câștiguri

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 oct. 2025, 22:20 UTC

Câștiguri

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 oct. 2025, 22:02 UTC

Câștiguri

Review & Preview: Earnings Extravaganza -- Barrons.com

28 oct. 2025, 21:42 UTC

Market Talk
Câștiguri

Global Equities Roundup: Market Talk

28 oct. 2025, 21:42 UTC

Market Talk
Câștiguri

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 oct. 2025, 21:20 UTC

Câștiguri

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 oct. 2025, 21:19 UTC

Câștiguri

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 oct. 2025, 21:18 UTC

Câștiguri

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Comparație

Modificare preț

Kala Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

931.25% sus

Prognoză pe 12 luni

Medie 8.25 USD  931.25%

Maxim 15 USD

Minim 1.5 USD

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruKala Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

4 ratings

1

Cumpărare

3

Păstrare

0

Vânzare

Date financiare

$

Despre Kala Pharmaceuticals Inc

Kala Pharmaceuticals Inc
help-icon Live chat